Logo image of SMX

SMX SECURITY MATTERS PLC (SMX) Stock Fundamental Analysis

NASDAQ:SMX - Nasdaq - IE000WZ90ZV5 - Common Stock - Currency: USD

2.3  +0.84 (+57.53%)

After market: 2.25 -0.05 (-2.17%)

Fundamental Rating

0

Taking everything into account, SMX scores 0 out of 10 in our fundamental rating. SMX was compared to 124 industry peers in the Electronic Equipment, Instruments & Components industry. SMX has a bad profitability rating. Also its financial health evaluation is rather negative. SMX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SMX has reported negative net income.
SMX had a negative operating cash flow in the past year.
SMX Yearly Net Income VS EBIT VS OCF VS FCFSMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

SMX's Return On Assets of -40.88% is on the low side compared to the rest of the industry. SMX is outperformed by 81.45% of its industry peers.
Looking at the Return On Equity, with a value of -182.24%, SMX is doing worse than 88.71% of the companies in the same industry.
Industry RankSector Rank
ROA -40.88%
ROE -182.24%
ROIC N/A
ROA(3y)-14.79%
ROA(5y)N/A
ROE(3y)-62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SMX Yearly ROA, ROE, ROICSMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SMX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMX Yearly Profit, Operating, Gross MarginsSMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

SMX has less shares outstanding than it did 1 year ago.
SMX has a worse debt/assets ratio than last year.
SMX Yearly Shares OutstandingSMX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 1M 2M 3M
SMX Yearly Total Debt VS Total AssetsSMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

SMX has an Altman-Z score of -2.51. This is a bad value and indicates that SMX is not financially healthy and even has some risk of bankruptcy.
SMX has a worse Altman-Z score (-2.51) than 85.48% of its industry peers.
SMX has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
SMX has a Debt to Equity ratio (0.20) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z -2.51
ROIC/WACCN/A
WACCN/A
SMX Yearly LT Debt VS Equity VS FCFSMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.04 indicates that SMX may have some problems paying its short term obligations.
SMX has a worse Current ratio (0.04) than 98.39% of its industry peers.
A Quick Ratio of 0.04 indicates that SMX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.04, SMX is doing worse than 98.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
SMX Yearly Current Assets VS Current LiabilitesSMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for SMX have decreased strongly by -76365.32% in the last year.
EPS 1Y (TTM)-76365.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SMX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMX Price Earnings VS Forward Price EarningsSMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SMX Per share dataSMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1K -2K -3K -4K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SMX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SMX SECURITY MATTERS PLC

NASDAQ:SMX (4/17/2025, 8:00:02 PM)

After market: 2.25 -0.05 (-2.17%)

2.3

+0.84 (+57.53%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.36%
Inst Owner Change-97.52%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap6.60M
AnalystsN/A
Price TargetN/A
Short Float %7.86%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4366.17
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.25
OCFYN/A
SpS0
BVpS4
TBVpS-13.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.88%
ROE -182.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.79%
ROA(5y)N/A
ROE(3y)-62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 364.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z -2.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76365.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-125.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1015.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-926.37%
OCF growth 3YN/A
OCF growth 5YN/A